CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)

Published:2010-01 Issue:1 Volume:20 Page:87-91
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:International Journal of Gynecological Cancer

Author:

Oaknin Ana,Barretina Pilar,Pérez Xavier,Jimenez Laura,Velasco Montserrat,Alsina Maria,Brunet Joan,Germà Josep Ramon,Beltran Miguel

Publisher

BMJ

Subject

Obstetrics and Gynaecology,Oncology

Reference19 articles.

1. Epithelial Ovarian Cancer: A Review of Current Management

2. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

3. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

4. New Guidelines to Evaluate the Response to Treatment in Solid Tumors

5. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Response to Anthracyclines in Ovarian Cancer;International Journal of Environmental Research and Public Health;2022-04-02

2. Liposomal therapies in oncology: does one size fit all?;Cancer Chemotherapy and Pharmacology;2018-08-16

3. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma;Archives of Gynecology and Obstetrics;2014-05-06

4. Short-Term Morbidity and Clinical Response After a 2-Week Versus 6-Week Interval From Debulking Surgery to Adjuvant Chemotherapy in Epithelial Ovarian Cancer;Clinical Ovarian and Other Gynecologic Cancer;2013-12

5. Aptamers from Cell-Based Selection for Bioanalytical Applications;Chemical Reviews;2013-03-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3